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Abstract
Background: The development of new therapeutic strategies for treatment of metastasized
colorectal carcinoma requires biologically relevant and adequate animal models that generate both
reproducible metastasis and the dissemination of tumor cells in the form of so-called minimal
residual disease (MRD), an expression of the systemic character of neoplastic disease.
Methods: We injected immunoincompetent nude mice intraportally with different numbers (1 ×
105, 1 × 106 and 5 × 106 cells) of the human colon carcinoma cell lines HT-29 and SW-620 and
investigated by histological studies and CK-20 RT-PCR the occurrence of hematogenous
metastases and the dissemination of human tumor cells in bone marrow.
Results: Only the injection of 1 × 106 cells of each colon carcinoma cell line produced acceptable
perioperative mortality with reproducible induction of hepatic metastases in up to 89% of all
animals. The injection of 1 × 106 cells also generated tumor cell dissemination in the bone marrow
in up to 63% of animals with hepatic metastases.
Conclusion:  The present intraportal injection model in immunoincompetent nude mice
represents a biologically relevant and adequate animal model for the induction of both reproducible
hepatic metastasis and tumor cell dissemination in the bone marrow as a sign of MRD.
Background
Colorectal carcinoma constitutes approximately 15% of
all cases of cancer and is one of the most common malig-
nant diseases worldwide. Despite multiple advances in its
diagnosis and treatment, 20% to 45% of patients with
colorectal carcinoma experience local recurrence and/or
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metastases with a consequent dramatic decline in progno-
sis. In the industrialized West, therefore, colorectal carci-
noma is the second most common cause of death from
cancer [1].
Metastases of colorectal carcinomas are initially localized
in the liver in 40% to 80% of patients. The principal cura-
tive treatment option is surgical resection, although only
one fourth of patients with liver metastases are operable
[2]. Following initial radical curative surgery, metastases
are attributed to the dissemination of tumor cells in the
form of minimal residual disease (MRD), whose prognos-
tic relevance continues to be discussed [3,4]. The classical
view is that metastatic spread is a late process in malignant
progression, but recent work suggested that dissemination
of primary cancer cells to distant sites like the bone mar-
row might be an early event [5].
In recent years marked improvements have been made in
the medicinal treatment of patients with colorectal carci-
nomas. New cytostatic agents and antibodies targeted
against EGFR and VEGF have increased median survival in
patients with advanced colorectal carcinomas to more
than 2 years, almost doubling the survival time of the 5-
FU era [6,7]. Reliable data are not available on the sequen-
tial application of available substances, an approach
which could further increase survival.
Alternative chemotherapeutic and immunological treat-
ment strategies are needed to further improve survival of
patients with metastasized colorectal carcinoma. Biologi-
cally accurate animal models can play an important role
in the development of such approaches and allow contin-
ued monitoring of their efficacy. For this purpose repro-
ducible growth rates are needed with reliable formation of
liver metastases and simultaneous induction and verifica-
tion of MRD. Animal studies based on surgical orthotopic
implantation are well capable of inducing liver metas-
tases, but they are limited by highly variable growth kinet-
ics and the need to prepare the tumor material in a
subcutaneous (s.c.) tumor animal model [8,9]. For this
reason numerous animal models involve injection of
colon carcinoma tumor cells directly into the liver paren-
chyma, the spleen, or portal vein to induce tumor growth
in the form of hepatic metastases of colorectal carcinoma
[10-12]. It remains largely unclear, however, whether
these animal models can induce the dissemination of
tumor cells in the early stage of cancer progression, caus-
ing recurrence.
The aim of the present study was to use the intraportal
injection of colorectal carcinoma cell lines in immunoin-
competent mice to establish reproducible systemic metas-
tases and dissemination of human carcinoma cells.
Methods
Animals
Six to 10-week-old female Balb/c nu/nu mice (Charles
River GmbH, Sulzfeld, Germany) weighing 16–18 g at the
time of surgery were used. The animals were kept in wire
cages in laminar air flow cabinets at a temperature of 20–
22°C, a humidity of 30–50%, and a 12-h/12-h light/dark
cycle. Autoclaved chow pellets (Altromin GmbH, Lage,
Germany) and autoclaved tap water were provided ad libi-
tum. The animal colonies were maintained in a specific
pathogen-free environment with regular screenings for
the presence of murine pathogens (such as Mycoplasma
pulmonis, Streptococcus pneumoniae, and Helicobacter
spp.). Housing and all procedures involving animals were
performed according to protocols approved by the Uni-
versity's animal care committee and in compliance with
the guidelines on animal welfare of the National Commit-
tee for Animal Experiments.
Cell lines
The human colon cancer cell lines HT-29 and SW-620
were propagated and cultured according to the distribu-
tor's protocol using McCoy's 5A medium modified and
supplemented with 10% heat-inactivated FBS, streptomy-
cin/penicillin (100 units/ml). Cells were cultured in a 5%
CO2 incubator at 37°C, and the medium was changed
every 3 days. Cultures were routinely tested for myco-
plasma contamination to ensure that only negative cells
were used.
Surgical procedure
For intraportal injection of HT-29 and SW-620 cells the
anesthetized animals were placed in a supine position.
After disinfection of the skin in the area of surgery a
median laparotomy was performed followed by mobiliza-
tion of the duodenum to liberate the portal vein. Different
numbers of tumor cells of both cell lines (1 × 105, 1 × 106
and 5 × 106 cells) in 200 μl PBS solution were injected into
the portal vein of 10 mice per group using a 32 G needle.
After removal of the needle bleeding was stopped by gen-
tly pressing the puncture site with a commercially availa-
ble cotton swab combined with a small piece of a styptic
cellulose fleece. The injection procedure was considered
successful if there was no post-injection bleeding from the
puncture site or recoil of tumor cells within the injection
canal or tumor cell spread into the abdominal cavity. After
tumor cell injection the intestine was repositioned and
the abdominal wall closed in a two-layer technique with
non-absorbable sutures. Mice were sacrificed at 30 days
post-injection or earlier if tumor related cachexy or
hepatic failure with tumor related ascites occurred. Liver
and lung tissue of all animals was collected and subjected
to histological examination after sacrificing the animals
by cervical dislocation. All surgical procedures were per-
formed in accordance with institutional guidelines.BMC Cancer 2009, 9:29 http://www.biomedcentral.com/1471-2407/9/29
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Histology
Liver and the lung tissue of all animals were examined his-
tological using standard hematoxylin and eosin staining.
The histological material was assessed by a consultant
pathologist.
Isolation of mononuclear cells
To obtain tumor cells from bone marrow, both femoral
bones of all animals were removed prior to dissection. The
bone marrow was washed out with phosphate-buffered
saline under sterile conditions. Mononuclear cell (MNC)
fractions of the bone marrow were isolated by Ficoll
(Pharmacia, Freiburg, Germany) density-gradient centrif-
ugation at 400 g for 30 min. As a control, MNC of animals
after intraportal injection of 0.9% saline were isolated in
the same way (n = 5).
Isolation of total RNA and cDNA synthesis
In all animals with hepatic metastases and in all control
mice total RNA was extracted from 1 × 106 MNC with 1 ml
Trizol reagent (Life Technologies GmbH, Karlsruhe, Ger-
many) and cDNA synthesis was performed according to
the manufacturer's recommendations (Applied Biosys-
tems GmbH, Weiterstadt, Germany).
CK-20 RT-PCR
The primers for human CK-20 are described by Weitz et al.
[13]. They developed a nested PCR protocol with outer
(first PCR) and nested (second PCR) primers. For the first
PCR, 5 ul of the cDNA synthesis mix were used at a final
volume of 50 μl 1× PCR buffer II containing 1.5 mM
MgCl2, 5 μM (each) of sense and antisense outer primer,
and 2.5 units of AmpliTaq DNA polymerase. The thermal
cycling condition comprised an initial denaturing step at
95°C for 10 min and 35 cycles at 95°C for 30 sec, 60°C
for 30 sec (annealing step), and 72°C for 30 sec (exten-
sion step) for 35 cycles, with a final extension step of 10
min. The second CK-20 PCR was performed in a manner
similar to the first PCR. Five micro liters of the first PCR
reaction were set up with nested primers at a final volume
of 50 μl. Thirty-five cycles of amplification were per-
formed at 30 sec intervals at temperatures of 95°C, 72°C,
and 72°C. Glyseraldehyde-3-phosphate dehydrogenase
(GAPDH) served as a control. The CK-20 primer pairs do
not amplify murine CK-20 [14]. PCR products were ana-
lyzed by electrophoresis on 2% agarose gel.
Results
Procedure-related mortality
Severe portal vein bleeding following intraportal injection
of tumor cells led to the death of one animal each after
injection of 1 × 105 and 1 × 106 cells. Injection of 5 × 106
cells of the cell lines HT-29 and SW-620 was followed
immediately by the death of one animal each, also due to
massive portal vein bleeding. Noteworthy were the deaths
within 24 hours of 2 animals after injection of 5 × 106 HT-
29 cells and of 3 animals after injection of 5 × 106 SW-620
cells following an initially unproblematic procedure. At
autopsy the cause of death was found to be large areas of
infarction in the liver parenchyma that apparently led to
acute liver failure. The overall injection-related mortality
from the injection of 5 × 106 cells of both cell lines was
35%.
Survival and tumor take rate
All animals surviving the injection of 1 × 105 cells of HT-
29 and SW-620 free of complications also survived the 30-
day study period and were sacrificed on the prearranged
date. Of the animals receiving 1 × 106 cells, one died on
the third day following injection of SW-620 cells. At
autopsy no macroscopic bleeding or liver infarction were
found, so the cause of death in this animal remains unex-
plained. All other animals in this injection group survived
the 30-day study period unimpaired and were sacrificed
on schedule.
The situation of the animals injected with 5 × 106 cells was
entirely different. As mentioned above, 7 of 20 animals
died during injection of the cell lines HT-29 or SW-620 or
within 24 hours thereof. One other animal died of
unknown causes on the fourth day post injection. On the
10th day following injection of 5 × 106 HT-29 cells, one
animal had to be sacrificed due to severe tumor cachexy
and swollen abdomen. Between the 10th and 20th days,
10 further animals exhibited such advanced tumor disease
that they too had to be sacrificed. The sole surviving ani-
mal receiving 5 × 106 cells had to be sacrificed on the 25th
day post injection, leaving not a single animal in this
series to reach the scheduled endpoint of 30 days.
In animals injected with 1 × 105 cells, liver metastases
occurred in 6 of 10 animals (60%) receiving HT-29 cells,
in 5 of 9 (56%) receiving SW-620 cells. After injection of
1 × 106 cells, 8 of 9 animals (89%) in the HT-29 group and
7 of 9 animals (78%) in the SW-620 group had metastases
in the liver parenchyma (Table). In both groups an aver-
age of 8 to 10, a few-mm-in-diameter, non-confluent liver
metastases were detected in otherwise intact murine liver
parenchyma. None of the animals were found to have pul-
monary metastases.
After injection of 5 × 106 cells of the HT-29 and SW-620
cell lines, all animals exhibited pronounced hepatic
metastases with almost complete destruction of the liver
parenchyma (Fig. 1). In the majority of animals, severe
tumor disease with cachexy and swollen abdomen was
seen between the 10th and 20th day after injection, none
of these animals, as mentioned above, survived to term. In
five animals each histologically confirmed pulmonaryBMC Cancer 2009, 9:29 http://www.biomedcentral.com/1471-2407/9/29
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metastases were found after injection of 5 × 106 cells of the
HT-29 and SW-620 cell lines.
Twenty-four of the 39 animals (61.5%) with hepatic and/
or pulmonary metastases were positive for CK-20 RT-PCR
indicating dissemination of tumor cells in the bone mar-
row. Thus MRD was demonstrated in slightly less than
two thirds of all animals with confirmed metastases after
intraportal injection of HT-29 or SW-620 cells. With an
increasing number of cells injected intraportally, the
number of animals with CK-20 positive bone marrow also
increased without reaching statistical differences in
fisher's exact test (Fig. 2).
Bone marrow of nude mice was proved for the presence of
disseminated tumor cells with a nested CK-20 RT-PCR in
a gastric cancer model [14]. The sensitivity of the CK-20
RT-PCR was determined in dilution experiments as previ-
ously described [15]. It is possible to detect less than ten
CK-20 positive tumor cells within 106 mononuclear cells.
The total number of animals investigated, the procedure
related mortality, the number with liver metastases, plus
the number of animals with RT-PCR-confirmed MRD is
shown in the table 1. A false positive signal was demon-
strated in one of the non-cancer control animals of this
study which is interpreted as a contamination since no
CK-20 RT-PCR signals of non-cancer control animals
could be detected in a different animal study (data not
shown) demonstrating the high specificity of the primer
pairs for human CK-20. In all RT-PCR experiments the
internal control with murine GAPDH [14] showed a pos-
itive signal.
Discussion
A basic sign of unfavorable prognosis in colorectal carci-
noma patients who have undergone curative resection is
the occurrence of distant metastases, mainly in the liver.
Complete destruction of the liver parenchyma in a nude  mouse on the 20th day after intraportal injection of 5 × 106  cells of the colon carcinoma cell line HT-29 Figure 1
Complete destruction of the liver parenchyma in a 
nude mouse on the 20th day after intraportal injec-
tion of 5 × 106 cells of the colon carcinoma cell line 
HT-29. Magnification: 40×, HE staining.
Rate of CK 20 positivity in bone marrow indicating MRD following intraportal injection of different numbers of SW-620 and  HT-29 cells in immunoincompetent mice Figure 2
Rate of CK 20 positivity in bone marrow indicating MRD following intraportal injection of different numbers of 




















6 cells BMC Cancer 2009, 9:29 http://www.biomedcentral.com/1471-2407/9/29
Page 5 of 7
(page number not for citation purposes)
Another prognostically unfavorable factor in solid gas-
trointestinal neoplasm is the presence of so-called mini-
mal residual disease (MRD), which is characterized in part
by the dissemination of tumor cells in bone marrow. Dis-
seminated tumor cells are held to be a possible cause of
the recurrence of cancer [16,17]. It is therefore essential
that animal models of human colorectal carcinomas sim-
ulate both hepatic metastases and MRD. The usefulness of
such a model would be increased when the results can be
reproduced within a relatively brief time period.
Although animal studies based on the orthotopic implan-
tation of human colorectal carcinoma tissue do simulate
the occurrence of liver metastases, they are limited by
highly variable growth kinetics and the need to prepare
tumor material in a s.c. tumor animal model [8,9,18]. The
recently described orthotopic microinjection of various
human colon carcinoma cell lines in nude mice showed a
sufficient metastases rate for individual cell lines, the
induction of MRD in this model, however, is unclear, as it
is in other reported intraportal, intrasplenic and intrahe-
patic injection models [19].
Intraportal injection of human colon carcinoma cell lines
directly simulates hematogenous tumor extension in
patients with colorectal carcinomas. The injection of
tumor cells into the spleen with subsequent splenectomy,
a technically simpler procedure than direct intraportal
injection, does also induce liver metastases reproducibly
[20]. Nevertheless we think that intraportal injection of
tumor cells mimic the natural metastatic process more
closely than intrasplenic injection does even considering
that intraportal injection of tumor cells circumvents the
early steps in the genesis of metastasis in colorectal carci-
noma. Although a rate of 10% portal venous thrombosis
following intraportal injection is described [21] we did
not observe any thrombotic complication in our series.
Nevertheless this model has convincing advantages, since
the metastases develop more rapidly than those in ortho-
topic xenotransplantation and thus avoid the non-T-cell-
mediated rejection mechanisms of immunoincompetent
animals, which are known to increase with increasing age
of the animals [22].
A vital prerequisite for a practical animal model is accept-
able perioperative mortality. In the present study this was
achieved in part by the use of an operation microscope
providing 16-fold magnification of the surgical field,
which allowed sufficiently careful insertion of the injec-
tion needle into the 1.5 mm-in-diameter vessel lumen of
the 16–18 g nude mice. If a 32-gauge needle is used, with-
drawal of the injection cannula can lead to massive bleed-
ing which led to the loss of 4 animals in the present study.
We were able to control the bleeding by applying cellulose
strips. Much more important for perioperative mortality
than blood loss, however, was the injection of larger cell
counts. Injection of 5 × 106 cells of each cell line was fol-
lowed by 2 and 3 additional deaths within 24 hours after
complication-free procedures. Autopsy revealed large,
wedge-shaped, partially confluent areas of infarction that
apparently led to acute liver failure in the affected ani-
mals. These may have resulted from the occlusion of large
intraparenchymal liver vessels due to the presence of
agglutinated tumor cells.
The injection of larger cell counts (5 × 106) not only
increased the perioperative mortality but also led to
higher tumor-related mortality over the 30-day study
period. By injecting 5 × 106 tumor cells of each of the 2 cell
lines we achieved a metastases rate of 100%. Unfortu-
nately, the rapid tumor growth led to such a rapid decline
in their general condition that all of the animals had to be
sacrificed prematurely. This situation certainly does not
simulate a continually developing tumor as a biologically
relevant animal model should. The high operation-related
and tumor-related mortality associated with the injection
Table 1: Results of all intraportal injections with different cell counts of the colon carcinoma cell lines HT-29 and SW-620.
Number of cells Cell line Total number of mice Procedure related 
mortality (%)
Total number of mice 
after injection
Number of mice with 
liver metastases (%)
Number of mice with 
cytokeratin positivity in 
bone marrow (%)
1 × 105 HT – 29 10 0% 10 60% (6/10) 50% (3/6)
SW – 620 10 10% 9 56% (5/9) 40% (2/5)
1 × 106 HT – 29 10 10% 9 89% (8/9) 63% (5/8)
SW – 620 10 0% 10 70% (7/10) 57% (4/7)
5 × 106 HT – 29 10 30% 7 100% (7/7) 86% (6/7)
SW – 620 10 40% 6 100% (6/6) 67% (4/6)BMC Cancer 2009, 9:29 http://www.biomedcentral.com/1471-2407/9/29
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of 5 × 106 tumor cells indicates that no more than 1 × 106
tumor cells should be injected in the intraportal injection
model in nude mice.
In solid gastrointestinal neoplasm, the dissemination of
tumor cells and/or MRD is regarded as a negative prognos-
tic factor since they may cause tumor recurrence [17,23].
Considering the systemic character of solid tumors [24],
MRD is characterized in part by the dissemination of
tumor cells in bone marrow. The induction of MRD in an
animal model therefore represents a highly promising
tool for the development of specific therapeutic
approaches.
Conclusion
In the present study, CK-20-positive cells corresponding
to disseminated tumor cells were detected in 24 of 39 ani-
mals with metastases following intraportal injection of
tumor cells, representing a relative frequency of 61.5% of
all animals irrespective of the injected cell counts. In the
group injected with 1 × 106 tumor cells, MRD was found
in about 60% of all animals with evident metastases. This
tumor animal model therefore does simulate the induc-
tion of systemic tumor disease in animals with metastases.
The fact that the differences in the rate of MRD following
intraportal injection of different numbers of tumor cells
did not reach statistical significance is due to the small
number of animals investigated. But the trend is evident.
The MRD rate in the present tumor animal model accords
with that reported by another work group, which investi-
gated MRD in a nude mouse model after orthotopic
implantation of a high-grade malignant gastric carcinoma
cell line [14].
Injection of human colon cancer cell lines in immunoin-
competent nude mice led to reproducible hepatic metas-
tases within a relatively short time period. The systemic
character of the malignant disease induced by the tumor
cell injection was confirmed for the first time by the dem-
onstration of disseminated tumor cells in bone marrow.
The present model is therefore well suited for the testing
and establishing of tumor-specific therapeutic
approaches.
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